| Pan-cancer whole-genome analyses of metastatic solid tumours P Priestley, J Baber, MP Lolkema, N Steeghs, E de Bruijn, C Shale, ... Nature 575 (7781), 210-216, 2019 | 914 | 2019 |
| Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance KJ Gotink, HJ Broxterman, M Labots, RR De Haas, H Dekker, ... Clinical Cancer Research 17 (23), 7337-7346, 2011 | 370 | 2011 |
| The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies L Angus, M Smid, SM Wilting, J van Riet, A Van Hoeck, L Nguyen, ... Nature genetics 51 (10), 1450-1458, 2019 | 296 | 2019 |
| The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs DL van der Velden, LR Hoes, H Van Der Wijngaart, ... Nature 574 (7776), 127-131, 2019 | 230 | 2019 |
| INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases R Beekhof, C van Alphen, AA Henneman, JC Knol, TV Pham, F Rolfs, ... Molecular systems biology 15 (4), e8250, 2019 | 93 | 2019 |
| Genomic landscape of metastatic colorectal cancer JC Haan, M Labots, C Rausch, M Koopman, J Tol, LJM Mekenkamp, ... Nature communications 5 (1), 5457, 2014 | 75 | 2014 |
| Therapeutic drug monitoring to individualize the dosing of pazopanib: a pharmacokinetic feasibility study D de Wit, NP van Erp, J den Hartigh, R Wolterbeek, ... Therapeutic drug monitoring 37 (3), 331-338, 2015 | 64 | 2015 |
| Evaluation of different phospho-tyrosine antibodies for label-free phosphoproteomics JC van der Mijn, M Labots, SR Piersma, TV Pham, JC Knol, ... Journal of proteomics 127, 259-263, 2015 | 60 | 2015 |
| Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features PAJ Mendelaar, M Smid, J van Riet, L Angus, M Labots, N Steeghs, ... Nature communications 12 (1), 574, 2021 | 59 | 2021 |
| Feasibility of label-free phosphoproteomics and application to base-line signaling of colorectal cancer cell lines SR Piersma, JC Knol, I de Reus, M Labots, BK Sampadi, TV Pham, ... Journal of proteomics 127, 247-258, 2015 | 58 | 2015 |
| Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells E Giovannetti, M Labots, H Dekker, E Galvani, JSW Lind, R Sciarrillo, ... Current pharmaceutical design 19 (5), 927-939, 2013 | 45 | 2013 |
| Strategies for kinome profiling in cancer and potential clinical applications: chemical proteomics and array-based methods SR Piersma, M Labots, HMW Verheul, CR Jiménez Analytical and bioanalytical chemistry 397, 3163-3171, 2010 | 43 | 2010 |
| Patients with rare cancers in the drug rediscovery protocol (DRUP) benefit from genomics-guided treatment LR Hoes, JM van Berge Henegouwen, H van der Wijngaart, LJ Zeverijn, ... Clinical Cancer Research 28 (7), 1402-1411, 2022 | 40 | 2022 |
| Sex-and site-specific differences in colorectal cancer risk among people with type 2 diabetes JA Overbeek, JG Kuiper, AAWA van der Heijden, M Labots, U Haug, ... International journal of colorectal disease 34, 269-276, 2019 | 39 | 2019 |
| Phosphotyrosine-based-phosphoproteomics scaled-down to biopsy level for analysis of individual tumor biology and treatment selection M Labots, JC van der Mijn, R Beekhof, SR Piersma, RR de Goeij-de Haas, ... Journal of proteomics 162, 99-107, 2017 | 31 | 2017 |
| Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer M Labots, KJ Gotink, H Dekker, K Azijli, JC Van Der Mijn, CM Huijts, ... Experimental & Molecular Medicine 48 (12), e279-e279, 2016 | 28 | 2016 |
| Patients with biallelic BRCA1/2 inactivation respond to olaparib treatment across histologic tumor types H Van Der Wijngaart, LR Hoes, JM van Berge Henegouwen, ... Clinical Cancer Research 27 (22), 6106-6114, 2021 | 25 | 2021 |
| Evaluation of the Khorana, PROTECHT, and 5‐SNP scores for prediction of venous thromboembolism in patients with cancer NAM Guman, RJ van Geffen, FI Mulder, TF van Haaps, V Hovsepjan, ... Journal of Thrombosis and Haemostasis 19 (12), 2974-2983, 2021 | 22 | 2021 |
| Mass spectrometry-based serum and plasma peptidome profiling for prediction of treatment outcome in patients with solid malignancies M Labots, LM Schütte, JC van der Mijn, TV Pham, CR Jiménez, ... The oncologist 19 (10), 1028-1039, 2014 | 21 | 2014 |
| Tumor drug concentration and phosphoproteomic profiles after two weeks of treatment with sunitinib in patients with newly diagnosed glioblastoma ME Van Linde, M Labots, CG Brahm, KE Hovinga, PC De Witt Hamer, ... Clinical Cancer Research 28 (8), 1595-1602, 2022 | 19 | 2022 |
